Suzuki, Kenji
Sameshima, Yukinori
Yokoyama, Junji
Terai, Shuji
Yoneyama, Hiroyuki
Atreya, Raja
Neurath, Markus F.
Hibi, Toshifumi
Asakura, Hitoshi
Funding for this research was provided by:
Stelic Institute & Co. Inc.
Article History
Received: 22 February 2024
Accepted: 11 April 2024
First Online: 25 April 2024
Declarations
:
: This study was approved by the ethics committee of the Sameshima Hospital (Approved No.72) and written informed consent was obtained from all participants.
: Not applicable.
: H.Y. was a founder of Stelic Institute & Co., and is an unpaid scientific advisor of GUT Inc. GUT Inc. has patents related to GUT-1 for the treatment of IBD. K.S. is an inventor of a patent related to submucosal injection. M.N. reports research grants and/or personal fees from Abbvie, MSD, Takeda, Boehringer, Roche, Pfizer, Janssen, Pentax and PPD. R.A. has served as a speaker, or consultant, or received research grants from AbbVie, Amgen, Arena Pharmaceuticals, Astra Zeneca, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Cellgene, Celltrion Healthcare, DrFalk Pharma, Galapagos, Gilead, InDex Pharmaceuticals, Janssen-Cilag, Lilly, MSD Sharp & Dohme, Novartis, Pandion Therapeutics, Pfizer, Roche Pharma, Samsung Bioepsis, Takeda Pharma, Viatris. T.H. has received lecture fees from, Abbvie GK, EA Pharma,Janssen, JIMRO, Mitsubishi-Tanabe Pharma, Mochida Pharmaceutical, Pfizer, Sand K.K.,Takeda Pharmaceutical, Zeria Pharmaceutical Co., Ltd., advisory/consultancy fees from Abbvie GK, Celltrion, EA Pharma, Eli Lilly, Gilead Sciences, Janssen, Mitsubishi-Tanabe Pharma, Nichi-Iko Pharmaceutical, Nippon Kayaku Co., Ltd. Takeda Pharmaceutical, Zeria Pharmaceutical and research grants from Abbvie GK, Activaid, Alfresa Pharma Corporation, JMDC Inc., Gilead Sciences, Inc., Nippon Kayaku Co., Ltd., Eli Lilly Japan K.K., Mochida Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K., Pfizer Japan Inc., Takeda Pharmaceutical Co., Ltd., Ferring Pharmaceuticals and Bristol-Myers Squibb; received scholarship contributions from Mitsubishi Tanabe Pharma Corporation, Zeria Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd.; Pfizer Japan Inc. belonged to study group sponsorship by Alfresa Pharma Corporation, JIMRO Co., Ltd., Kyorin Pharmaceutical Co., Ltd., and Mochida Pharmaceutical Co., Ltd. Miyarisan Pharmaceutical Co., Ltd., Zeria Pharmaceutical Co., Ltd. S.T. has received lecture fees from Gilead Sciences, MSD, Daiichi-Sankyo Co., Ltd., Asuka Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd. Other authors have no conflict of interest.